Published in final edited form as:

Tetrahedron. 2008 January 7; 64(2): 433–438. doi:10.1016/j.tet.2007.10.054.

Carbocyclic 4'-*Epiformycin*

Jian Zhou, Minmin Yang, Akin Akdag, Haisheng Wang, and Stewart W. Schneller*

Department of Chemistry and Biochemistry, Auburn University, Auburn, Alabama 36849-5312

Abstract

Formycin is a naturally occurring biologically responsive C-nucleoside. In pursuing the design and syntheses of novel C-nucleosides, convenient access to carbocyclic C-nucleosides based on the formycin framework was a goal. One such target was carbocyclic 4'-*epiformycin* (**4**). This compound is reported via a procedure based on an asymmetric aldol/ring closure methathesis strategy. To provide a preliminary glimpse into the biological characterization of **4** an antiviral assay was conducted. Target **4** was found to be inactive and to lack cytotoxicity to the host cells.

Keywords

cyclopentyl; C-nucleoside; pyrazolo[4,3-*d*]pyrimidine; diastereomeric aldol

Introduction

Formycin A (**1**) is the C-nucleoside isomer of adenosine, which has achieved a place of potential that has not been fully developed for its value in medicinal agent discovery.¹ Similarly, but more thoroughly studied, is the carbocyclic adenine derivative aristeromycin (**2**).² Little attention³ has been devoted to combining these two structural features into carbocyclic C-nucleosides (for example, carbocyclic formycin A, **3**) as a source for a new chemotherapeutic library. Our goal is to gain access to representatives of this latter group of compounds. The 4'-epimer of **3** (that is, **4**), which is an analog of α -L-lyxoadenosine,⁴ is a member of that series and it is described herein.

Chemistry

The plan to **4** required the availability of the cyclopentyl alkyne **5** as the starting material for construction of the requisite pyrazolo[4,3-*d*]pyrimidine base unit.^{3d,3e,5a-c,e} Because of the numerous examples of stereoselective epoxide ring openings as synthetic sequence components,⁶ **5** was seen as being accessible from the chiral **6** and an alkynyl organoaluminum reagent.⁷ To gain access to **6**, we adapted literature conditions^{8–10} beginning with (*R*)-4-benzyl-2-oxazolidinone (**8**) (Scheme 1) and called on asymmetric aldol/ring closure metathesis steps.

With **6** in hand, its reaction with diethyl[(trimethylsilyl)ethynyl]aluminum resulted in **13** (Scheme 2) and a minor side-product assigned as **14**.¹¹ Desilylation of **13** yielded **5**, whose X-

*Corresponding author. Tel.: 334-844-5737; fax: 334-844-5748; e-mail: schnest@auburn.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ray crystallographic analysis (Figure 3) confirmed that the hydroxy, benzyloxy, benzyloxymethyl were on same face of cyclopentyl ring and opposite to the alkynyl unit.

Formylation **5** and subsequent reaction of the resultant substituted propargylic aldehyde with hydrazine and then acetylation provided **15**.^{3d,3e} Debenzylation (boron tribromide was superior to catalytic hydrogenolysis) of **15** then acetylation (to **16**) was followed by nitration and *cine*-cyano substitution^{3d,3e,5c-5e} to yield **17**. Hydrogenation of **17** gave **18**. Deacetylation of **18** (to **19**) and subsequent treatment with formamidine^{3d,3e,5c,5e} produced the fused pyrimidine target **4**.

Antiviral Analysis

To gain preliminary insight into the biological potential of **4**, it was subjected to antiviral screening versus herpes simplex-1, herpes simplex-2, herpes simplex-1 (TK⁻), vaccinia, vesicular stomatitis, coxsackie B4, respiratory syncytial, parainfluenza 3, reovirus-1, Sinbis, and Punta Toro.¹² No activity was found. Also, no cytotoxicity arose in the cell lines used in the antiviral assays: human erythroleukemia (HEL), HeLa, and Vero.

Conclusion

A straightforward chiral synthesis of carbocyclic 4'-*epi*formycin has been achieved using practical means and avails a rare example of a 4'-*epi* carbocyclic nucleoside.¹³ The absence of antiviral activity with **4** may be the consequence of its failure to undergo conversion to the 5'-nucleotide derivative, an efficient intracellular process for the parent formycin,¹⁴ and/or its lack of inhibitory effect on S-adenosylhomocysteine hydrolase, a site of action of aristeromycin (**3**).²

Experimental

Materials and Methods

Melting points were recorded on a Meltemp II melting point apparatus and are uncorrected. ¹H and ¹³C NMR spectra were recorded on a Bruker AV- 400 spectrometer (operated at 400 or 250 MHz, respectively). All ¹H chemical shifts are reported in δ relative to internal standard tetramethylsilane (TMS, δ 0.00). ¹³C chemical shifts are reported in δ relative to CDCl₃ (center of triplet, δ 77.23). The spin multiplicities are indicated by the symbols s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad), dd (doublet of doublet). Elemental analyses were performed by Atlantic Microlabs, Atlanta, Georgia. Reactions were monitored by thin layer chromatography (TLC) using 0.25 mm E. Merck silica gel 60-F₂₅₄ precoated silica gel plates with visualization by irradiation with a Mineral light UVGL-25 lamp or exposure to iodine vapor. Column chromatography was performed on Whatman silica gel (average particle size 5–25 μ m, 60 Å) and elution with the indicated solvent system. Yields refer to chromatographically and spectroscopically (¹H and ¹³C NMR) homogeneous materials. The reactions were generally carried out in a N₂ atmosphere under anhydrous conditions.

(4*R*)-Benzyl-3-(pent-4-enoyl)oxazolidin-2-one (**9**)

Triethylamine (15.3 mL, 0.11 mol) was added to a solution of 4-pentenoic acid (11.6 mL, 11.3 g, 0.11 mol) in *t*-butyl methyl ether (800 mL) cooled to –78 °C. The solution was stirred for 5 min, and pivaloyl chloride (13.5 mL, 0.11 mol) was added. After 15 min, the bath was removed and replaced by an ice H₂O bath. The heterogeneous mixture (containing **a**) was mechanically stirred at 0 °C for 1 h. In a separate flask, a solution of (*R*)-4-benzyl-2-oxazolidinone (**8**, 19.2 g, 0.11 mol) in THF (200 mL) was cooled to –78 °C, whereupon *n*-BuLi (44.0 mL, 2.5 M in hexanes, 0.11 mol) was added slowly. This solution was stirred for 10 min at –78 °C. The flask

containing the mixed anhydride was cooled to -78°C , and the lithiated oxazolidinone transferred via cannula into the mixed anhydride **a**. After being stirred at -78°C for 15 min, the reaction mixture was warmed to 0°C and stirred for 30 min, then the reaction was quenched by addition of aqueous, saturated NH_4Cl . After extraction twice with CH_2Cl_2 , the combined organic phases were dried (anhyd. Na_2SO_4), filtered and the filtrate concentrated. Purification by flash silica gel column chromatography (hexanes/EtOAc, 3:1) gave **9** (28.5 g, 100%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 2.42 (m, 2H), 2.76 (dd, 1H, $J = 9.4, 13.4$ Hz), 3.03 (m, 2H), 3.24 (dd, 1H, $J = 10.1, 13.4$ Hz), 4.12 (m, 2H), 4.64 (m, 1H), 5.04 (m, 2H), 5.86 (m, 1H), 7.28 (m, 5H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.6, 35.2, 38.2, 55.5, 66.6, 116.0, 127.7, 129.3, 129.8, 135.8, 137.2, 153.8, 172.8. Anal. Calcd for $\text{C}_{15}\text{H}_{17}\text{NO}_3$: C, 69.48; H, 6.61; N, 5.40. Found: C, 69.44; H, 6.65; N, 5.31.

[3(2*R*,3*S*),4*R*]-3-(2-Allyl-3-hydroxypent-4-enoyl)-4-benzylloxazolidin-2-one (10)

To a solution of **9** (26 g, 0.10 mol) in CH_2Cl_2 (50 mL) at -78°C under N_2 atmosphere was added diisopropylethylamine (39 mL, 0.22 mol) followed by dibutylboron triflate (200 mL, 0.20 mol, 1.0M solution in CH_2Cl_2). The reaction mixture was allowed to stir for 1 h at room temperature. After re-cooling to -78°C , a solution of acrolein (16 mL, 0.22 mol) in CH_2Cl_2 (100 mL) was added dropwise. The mixture was stirred for 2 h at -78°C . Then, the reaction mixture was slowly warmed to room temperature and allowed to stir overnight. It was quenched with saturated NaHCO_3 solution and extracted with CH_2Cl_2 . The organic phase was washed with brine, dried (anhyd. Na_2SO_4), filtered, and the filtrate evaporated under reduced pressure. Purification of the residue *via* silica gel flash chromatography (gradient elution from 10 % to 25 % EtOAc: hexanes) afforded **10** (29 g, 92 %) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 2.52 (m, 1H), 2.66 (m, 2H), 2.86 (br s, 1H), 3.31 (m, 1H), 4.18 (m, 2H), 4.29 (m, 1H), 4.47, (br s, 1H), 4.73 (m, 1H), 5.24 (m, 4H), 5.91 (m, 2 H), 7.32 (m, 5H). ^{13}C NMR (100 MHz, CDCl_3) δ 32.1, 38.1, 47.4, 55.7, 66.1, 73.4, 116.9, 117.4, 127.5, 129.1, 129.6, 135.3, 135.4, 137.4, 153.7, 174.5. Anal. Calcd for $\text{C}_{18}\text{H}_{21}\text{NO}_4$: C, 68.55; H, 6.71; N, 4.44. Found: C, 68.20; H, 7.07; N, 4.11.

[3(1*R*,2*S*),4*S*]-4-Benzyl-3-(2-hydroxycyclopent-3-enecarbonyl)oxazolidin-2-one (11)

A solution of compound **10** (22.2 g, 70.4 mmol) in CH_2Cl_2 (300 mL) was degassed by passing through a stream of N_2 for 25 min and 0.5 mol% of Grubbs' catalyst (first generation) was then added under an atmosphere of N_2 . After stirring overnight, the reaction mixture was exposed to air for 1 h, and purified by flash silica gel column chromatography (hexanes/EtOAc, 1:1) to yield **11** (12 g, 59%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 2.43 (m, 1H), 2.76 (m, 1H), 2.86 (d, 1H, $J = 7.5$ Hz), 3.14 (m, 1H), 3.27 (m, 1H), 4.09 (m, 1H), 4.22 (m, 1H), 4.40 (m, 1H), 4.69, (m, 1H), 5.10 (br s, 1H), 5.72 (m, 1H), 5.99 (m, 1H), 7.26 (m, 5H). ^{13}C NMR (100 MHz, CDCl_3) δ 33.0, 37.9, 47.2, 55.4, 66.2, 76.9, 127.2, 128.8, 129.4, 130.9, 134.4, 135.5, 153.7, 172.0. Anal. Calcd for $\text{C}_{16}\text{H}_{17}\text{NO}_4$: C, 66.89; H, 5.96; N, 4.88. Found: C, 66.69; H, 6.04; N, 4.71.

(1*S*,5*S*)-5-Hydroxymethyl-2-cyclopenten-1-ol (7)

A solution of LiBH_4 (1.0 g, 43.0 mmol) in THF (55 mL) cooled at 0°C was added into a solution of **11** (11.0 g, 38.3 mmol) in THF (150 mL) and MeOH (1.7 mL). The reaction mixture was stirred at 0°C for 45 min and then allowed to warm to room temperature. After 1 h, 10% NaOH (61 mL) was added, and the stirring continued until both phases were clear. The mixture was extracted with Et_2O . The organic phase was washed with brine, dried (anhyd. Na_2SO_4), filtered, and the filtrate concentrated *in vacuo*. Purification by silica gel flash chromatography (gradient elution from 50% to 70% EtOAc/hexanes) yielded **7** (2.9 g, 66.3%) as a colorless liquid, $[\alpha]_{\text{D}}^{22.8} 124.0^{\circ}$ (c, 0.26, methanol) (lit.¹⁰ reported $[\alpha]_{\text{D}}^{24} -125.1^{\circ}$ (c, 0.47, CH_2Cl_2) for the enantiomer of **7**). ^1H NMR (400 MHz, CDCl_3) δ 2.19 (m, 1H), 2.37 (m, 2H), 3.75 (br s,

2H), 4.24 (d, 2H, $J=16.8$ Hz), 4.85 (br s, 1H), 5.81 (m, 1H), 5.97 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 33.6, 42.7, 62.2, 76.9, 132.4, 134.7. Anal. Calcd for $\text{C}_6\text{H}_{10}\text{O}_2$: C, 63.14; H, 8.83. Found: C, 63.04; H, 8.98.

(1S,2R,3S,4S)-1-Benzyloxymethyl-2-benzyloxy-3,4-epoxycyclopentane (6)

A solution of **7** (2.1 g, 18.4 mmol), *m*-chloroperoxybenzoic acid (7.2 g) and CH_2Cl_2 (100 mL) was stirred at room temp overnight. The solvent was removed and the residue partitioned between Et_2O and H_2O . The solvent was then removed *in vacuo* to obtain **12** (2.2 g), which was used in the next step without further purification. ^1H NMR (400 MHz, CDCl_3) δ 2.02 (m, 1H), 2.13 (m, 1H), 2.43 (m, 1H), 3.40 (m, 2H), 3.52 (m, 1H), 3.61 (m, 1H), 3.69 (m, 2H), 4.60 (dd, 1H, $J = 1.5, 9.0$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 31.4, 37.8, 56.2, 61.5, 64.0, 75.2.

To a solution of **12** (2.2 g) in anhydrous THF (50 mL) at 0 °C, NaH (2 g, 50 mmol, 60% dispersion in mineral oil) was added in several portions. After 30 min, benzyl bromide (6.1 mL, 51.3 mmol) and a catalytic amount of tetrabutylammonium iodide were added. The reaction mixture was then allowed to stir at room temp overnight. After the starting material was no longer present (TLC), ice H_2O was added to quench the reaction. The resultant mixture was extracted with CH_2Cl_2 . The combined extracts were washed with brine, dried (anhyd. Na_2SO_4), filtered and the filtrate concentrated *in vacuo*. The residue was purified by silica gel flash column chromatography (hexanes/ EtOAc , 4:1) afforded **6** (4.1 g, 72% over 2 steps) as an oil. ^1H NMR (400 MHz, CDCl_3) δ 1.92 (m, 1H), 2.32 (d, 1H, $J = 14.9$ Hz), 2.53 (m, 1H), 3.48 (m, 1H), 3.58 (m, 2H), 3.90 (dd, 1H, $J = 4.7, 9.2$ Hz), 4.23 (dd, 1H, $J = 1.2, 8.5$ Hz), 4.56 (s, 2H), 4.70 (q, 2H, $J = 12.0$ Hz), 7.41 (m, 10H). ^{13}C NMR (100 MHz, CDCl_3) δ 30.2, 35.7, 54.9, 57.8, 72.5, 72.6, 73.7, 80.9, 127.6, 127.7, 127.9, 128.0, 128.5, 128.6, 138.3, 138.9. Anal. Calcd for $\text{C}_{20}\text{H}_{22}\text{O}_3$: C, 77.39; H, 7.14. Found: C, 77.42; H, 7.10.

(1S,2R,3S,5S)-2-Benzyloxy-3-benzyloxymethyl-5-(trimethylsilylethynyl)-cyclopentanol (13)

To a solution of trimethylsilylacetylene (15.3 mL, 108.2 mmol) in anhydrous toluene (390 mL) with stirring at -78 °C under N_2 was added *n*-butyllithium (43.3 mL, 108.3 mmol, 2.5 M solution in hexanes), and the reaction mixture was stirred at the same temperature for 30 min. Then, a solution of diethylaluminum chloride (60.1 mL, 108.2 mmol, 1.8 M solution in toluene) was added at 0 °C. Upon the addition a slow precipitation of LiCl was observed. The reaction mixture was stirred for 5 h at 10 °C. A solution of epoxide **6** (6.6 g, 21.3 mmol) in toluene (20 mL) was then added immediately. The reaction mixture was stirred at 0 °C for 45 min and 3 h at room temperature, monitored by TLC analysis, and quenched with MeOH (CAUTION: gas evolution). After adding H_2O (4.2 mL), 15% NaOH solution (4.2 mL), and H_2O (12.6 mL), the reaction mixture was filtered, washed with CH_2Cl_2 , and the organic layer then washed with brine, and dried (anhyd. Na_2SO_4). The solvent was evaporated, and the crude residue was purified by silica gel column chromatography (hexanes/ EtOAc , 6:1) to give **13** (5.4 g, 62%) as a white solid, mp 47–48 °C. ^1H NMR (250 MHz, CDCl_3) δ 0.24 (s, 9H), 1.98 (m, 2H), 2.64 (m, 1H), 2.91 (m, 1H), 3.33 (m, 1H), 3.62 (m, 2H), 4.21 (m, 2H), 4.61 (s, 2H), 4.74 (d, 2H, $J=2.8$ Hz), 7.41 (m, 10H). ^{13}C NMR (62.5 MHz, CDCl_3) δ 0.46, 31.8, 36.7, 39.8, 69.4, 73.6, 78.4, 80.9, 85.9, 109.2, 128.0 (2C), 128.1 (2C), 128.5 (2C), 128.7 (2C), 138.6. Anal. Calcd for $\text{C}_{25}\text{H}_{32}\text{O}_3\text{Si}$: C, 73.49; H, 7.89. Found: C, 73.36; H, 7.93.

Further elution of the column gave **14** (1.8 g, 24.4%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 2.01 (m, 1H), 2.31 (m, 1H), 2.65 (m, 1H), 3.48 (dd, 1H, $J=5.7, 9.1$ Hz), 3.56 (dd, 1H, $J=4.3, 9.1$ Hz), 3.75 (m, 1H), 4.15 (m, 2H), 4.30 (dd, 1H, $J=4.1, 7.7$ Hz), 4.51 (s, 2H), 4.60 (dd, 2H, $J=11.4, 36.9$ Hz), 7.31 (m, 10H). ^{13}C NMR (100 MHz, CDCl_3) δ 34.7, 38.7, 62.2, 68.6, 73.2, 73.5, 78.3, 79.3, 127.8 (2C), 128.0 (2C), 128.6 (2C), 137.7, 138.2. Anal. Calcd for $\text{C}_{20}\text{H}_{23}\text{ClO}_3$: C, 69.26; H, 6.68. Found: C, 69.17; H, 6.73.

(1S,2R,3S,5S)-2-Benzyloxy-3-benzyloxymethyl-5-ethynylcyclopentanol (5)

To a solution of **13** (3.2 g, 7.8 mmol) in THF (60 mL) under N₂ was added of tetrabutylammonium fluoride (7.8 mL, 7.8 mmol, 1 M solution in THF) by injection at 0 °C. The mixture was stirred for overnight at room temperature. The solution was absorbed on silica gel, and the crude product purified by silica gel flash column chromatography (hexanes/EtOAc, 4:1) to give **5** (2.4 g, 92%) as a white solid, mp 66–67 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.84 (m, 1H), 1.96 (m, 1H), 2.11 (d, 1H, *J*=2.5 Hz), 2.54 (m, 1H), 2.78 (m, 1H), 3.19 (d, 1H, *J*=8.7 Hz), 3.53 (m, 2H), 4.12 (m, 2H), 4.51 (m, 2H), 4.64 (dd, 2H, *J*=11.5, 13.7 Hz), 7.30 (m, 10H). ¹³C NMR (100 MHz, CDCl₃) δ 31.4, 35.4, 39.7, 69.3, 69.9, 73.5, 73.6, 78.3, 80.9, 86.6, 127.9 (2C), 128.6 (2C), 128.7 (2C), 138.1, 138.5. Anal. Calcd for C₂₂H₂₄O₃: C, 78.54; H, 7.19. Found: C, 78.56; H, 7.22.

(1S,2R,3S,5S)-1-Acetyl-5-(1-acetyl-1*H*-pyrazol-3-yl)-2-benzyloxy-3-(benzyloxymethyl)cyclopentane (15)

To a solution of **5** (2.4 g, 7.1 mmol) in anhydrous *t*-butyl methyl ether (90 mL) with stirring at –78 °C under N₂ was added *n*-butyllithium (7.1 mL, 17.8 mmol, 2.5 M solution in hexanes), and the reaction mixture stirred at the same temperature for 30 min. An excess of DMF (2.7 mL, 35.0 mmol) was added in one portion and the cold bath removed. The reaction mixture was allowed to warm to room temperature and aged for 30 min. The TBME solution was poured into a vigorously stirred, biphasic solution prepared from a 10% aqueous solution of KH₂PO₄ (45 mL) and TBME (45 mL) cooled over ice to ca. +5 °C. The resulting layers were separated and the organic extract was washed with H₂O. The combined aqueous layers were back extracted with TBME. The combined organic layers were dried (anhyd. Na₂SO₄), filtered and the filtrate concentrated to give the crude acetylenic aldehyde as an oil. The crude product thus isolated was committed to the next step without further purification.

To a solution of crude aldehyde (from the previous process) in glacial AcOH (78 mL) was added a solution of hydrazine monohydrate (3.7 g, 34.9 mmol) in glacial AcOH (38 mL). The resulting solution was heated at reflux for 8 h and then concentrated *in vacuo* to afford a dark brown oil. This crude product was dissolved in pyridine (20 mL) and Ac₂O (9.3 mL, 98.4 mmol) and DMAP were added. The resulting solution was stirred for 16 h at room temperature. The solvent was removed *in vacuo*, and the crude residue dissolved in EtOAc (800 mL), washed with 10% HCl and brine, dried (anhyd. Na₂SO₄), concentrated, and purified by silica gel column chromatography to afford **15** (2.8 g, 85% over 3 steps) as a light yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 1.99 (s, 3H), 2.00 (m, 2H), 2.63 (s, 3H), 2.95 (m, 1H), 3.48 (dd, 1H, *J*=6.4, 9.0 Hz), 3.60 (m, 1H), 3.72 (t, 1H, *J*=8.7 Hz), 4.29 (t, 1H, *J*=4.0 Hz), 4.50 (dd, 2H, *J*=11.9, 13.6 Hz), 4.60 (q, 2H, *J*=11.6 Hz), 5.20 (dd, 1H, *J*=3.7, 9.4 Hz), 6.28 (d, 1H, *J*=2.8 Hz), 7.29 (m, 10H), 8.14 (d, 1H, *J*=2.8 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 21.1, 21.8, 29.9, 39.3, 40.4, 69.8, 73.3, 74.1, 79.6, 80.5, 108.7, 127.7, 127.7, 127.8, 127.8, 128.5, 128.5, 129.1, 138.5, 138.9, 159.0, 169.6, 170.8. Anal. Calcd for C₂₇H₃₀N₂O₅: C, 70.11; H, 6.54; N, 6.06. Found: C, 70.10; H, 6.48; N, 6.08.

(1S,2R,3S,5S)-1,2-Diacetoxy-5-acetoxymethyl-3-(1-acetyl-1*H*-pyrazol-3-yl)-cyclopentane (16)

To a stirred solution of **15** (2.0 g, 4.3 mmol) in anhydrous CH₂Cl₂ (180 mL) was added boron tribromide (43.2 mL, 43.2 mmol, 1.0 M solution in CH₂Cl₂) at –78 °C and the reaction mixture stirred at the same temperature for 1 h. To this mixture was added MeOH (400 mL) and the reaction mixture neutralized with Ag₂CO₃ and filtered through a pad of Celite. The filtrate was evaporated and the crude product dissolved in CH₂Cl₂ (300 mL). To this triethylamine (4.8 mL), Ac₂O (1.9 mL) and a catalytic amount of DMAP were added, and the resulting solution stirred overnight. The mixture was then washed with brine, dried (anhyd. Na₂SO₄), concentrated, and the residue chromatographed (silica gel, hexanes/EtOAc, 3:1) to afford **16** (1.2 g, 76% over 2 steps) as a syrup. ¹H NMR (400 MHz, CDCl₃) δ 2.07 (m, 11H), 2.66 (m,

3H), 3.56 (m, 1H), 4.11 (m, 3H), 5.35 (m, 1H), 5.55 (m, 1H), 6.30 (m, 1H), 8.18 (d, 1H, $J=2.5$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 20.9, 21.0, 21.1, 21.9, 29.8, 37.9, 39.3, 62.9, 73.3, 78.1, 108.6, 129.5, 157.8, 170.3 (2C), 170.4, 171.2. Anal. Calcd for $\text{C}_{17}\text{H}_{22}\text{N}_2\text{O}_7$: C, 55.73; H, 6.05; N, 7.05. Found: C, 55.85; H, 6.19; N, 7.67.

(1S,2R,3S,5S)-1,2-Diacetoxy-5-acetoxymethyl-3-(5-cyano-4-nitro-1H-pyrazol-3-yl)cyclopentane (17)

Trifluoroacetic anhydride (2.1 mL) was added dropwise to a stirred solution of **16** (0.99 g, 2.7 mmol) and ammonium nitrate (1.9 g) in TFA (30 mL) at 0 °C. The resulting solution was allowed to warm to room temperature and stirred overnight. The solvent was evaporated *in vacuo* at room temperature and then diluted with CH_2Cl_2 , washed with H_2O , sat. aqueous NaHCO_3 solution and brine, dried (anhyd. Na_2SO_4), and the organic phase concentrated *in vacuo* to give the 1,4-dinitro pyrazole derivative (1.1 g) as a syrup. The crude product thus isolated was committed to the next step without further purification.

At room temperature, a solution of the 1,4-dinitro compound in EtOH (9.3 mL) and EtOAc (9.3 mL) was added dropwise over 5 min to a stirred solution of KCN (1.3 g, 19.5 mmol) in EtOH (23.0 mL) and H_2O (5.5 mL). Following an additional 5 min at room temp, the reaction mixture was neutralized with AcOH (2.0 mL). After evaporation of the solvent *in vacuo*, the residue was diluted with EtOAc (110 mL), washed with H_2O and brine, dried (anhyd. Na_2SO_4) and concentrated *in vacuo* to a residue that was subjected to chromatographic purification (silica gel, $\text{CH}_2\text{Cl}_2/\text{MeOH}$, 20:1) to afford **17** (0.94 g, 88% over 2 steps) as a light yellow syrup. ^1H NMR (400 MHz, CDCl_3) δ 2.00 (s, 3H), 2.09 (s, 3H), 2.11 (m, 2H), 2.21 (s, 3H), 2.36 (m, 1H), 2.96 (m, 1H), 4.21 (m, 3H), 5.58 (m, 1H), 5.64 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 20.6, 20.7, 20.8, 30.0, 36.9, 37.8, 62.5, 72.9, 76.4, 110.7, 122.6, 133.9, 145.0, 170.6, 171.4, 171.8. Anal. Calcd for $\text{C}_{16}\text{H}_{18}\text{N}_4\text{O}_8$: C, 48.73; H, 4.60; N, 14.21. Found: C, 48.29; H, 4.59; N, 13.90.

(1S,2R,3S,5S)-1,2-Diacetoxy-3-acetoxymethyl-5-(4-amino-5-cyano-1H-pyrazol-3-yl)cyclopentane (18)

A catalytic amount of Pd/C was added to a solution of **17** (0.83 g, 2.1 mmol) in MeOH (30 mL). The resulting mixture was shaken under 30 psi of H_2 overnight. After the reaction was complete, the solvent was evaporated *in vacuo* and the product purified by silica gel chromatography ($\text{CH}_2\text{Cl}_2/\text{EtOAc}/\text{MeOH}$, 8:1:0.5) to afford **18** (0.7 g, 92%) as a syrup. ^1H NMR (400 MHz, CDCl_3) δ 2.07 (m, 14H), 2.72 (m, 1H), 3.51 (m, 1H), 4.12 (m, 2H), 5.28 (m, 1H), 5.50 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 20.9 (2C), 21.1, 28.7, 36.4, 37.8, 63.1, 73.1, 78.0, 110.1, 112.6, 133.8, 135.7, 170.4, 171.0, 171.4. Anal. Calcd for $\text{C}_{16}\text{H}_{20}\text{N}_4\text{O}_6$: C, 52.74; H, 5.53; N, 15.38. Found: C, 52.81; H, 5.89; N, 15.62.

(1S,2R,3S,5S)-1,2-Dihydroxy-3-hydroxymethyl-5-(4-amino-5-cyano-1H-pyrazol-3-yl)cyclopentane (19)

Anhydrous NH_3 was introduced to a solution of compound **18** (0.59 g, 1.6 mmol) in MeOH (80 mL) at 0 °C. The reaction mixture was stirred at room temperature. After the starting material was no longer present (TLC), the solvent was removed *in vacuo* and the residue purified by silica gel chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 6:1) to afford **19** (0.33g, 88%) as a light yellow solid, mp 174–176 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.73 (m, 2H), 2.08 (m, 1H), 3.18 (m, 1H), 3.37 (m, 1H), 3.60 (m, 1H), 3.89 (m, 2H), 4.34 (m, 3H), 4.52 (m, 1H), 4.75 (m, 1H), 13.17 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 29.2, 37.1, 41.9, 61.0, 72.7, 79.1, 114.1, 115.4, 131.7, 132.9. Anal. Calcd for $\text{C}_{10}\text{H}_{14}\text{N}_4\text{O}_3$: C, 50.41; H, 5.92; N, 23.52. Found: C, 50.39; H, 6.03; N, 23.35.

(1*S*,2*R*,3*S*,5*S*)-1,2-Dihydroxy-3-hydroxymethyl-5-(7-amino-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-yl)cyclopentane (4)

A solution of **19** (0.25 g, 1.0 mmol) in EtOH (30 mL) was stirred with formamidine acetate (0.16 g, 1.5 mmol) under reflux for 50 min. The resulting white precipitate was isolated by filtration, washed with EtOH, and dried to afford analytically pure **4** (0.16 g, 60%) as a white solid, mp 269–270 °C (dec.): $[\alpha]_D^{22.5}$: -53.5° (*c*, 0.26, DMSO). ^1H NMR (400 MHz, CDCl_3) δ 1.83 (m, 2H), 2.28 (m, 1H), 3.41 (m, 2H), 3.62 (m, 1H), 3.98 (m, 1H), 4.34 (m, 3H), 4.94 (s, 1H), 7.24 (br s, 2H), 8.13 (s, 1H), 12.37 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 30.8, 40.1, 42.8, 61.3, 73.3, 79.0, 122.2, 139.8, 148.2, 150.8, 151.2. Anal. Calcd for $\text{C}_{11}\text{H}_{15}\text{N}_5\text{O}_3$: C, 49.81; H, 5.70; N, 26.40. Found: C, 50.00; H, 5.83; N, 26.30.

X-ray data for compound 5

Crystallographic data (excluding structure factors) for **5** has been deposited with Cambridge Crystallographic Data Centre as supplementary publication number CCDC 642212. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44(0)1223-336033 or e mail: deposit@ccdc.cam.ac.uk].

Acknowledgments

This research has been supported by funds from the Department of Health and Human Services (AI 56540), which is appreciated. We are also indebted to the following individuals for providing the antiviral data¹² following their standard protocols: Dr. Erik De Clercq, the Rega Institute, Leuven Belgium; Dr. Earl Kern, University of Alabama at Birmingham, Birmingham, AL; Dr. Robert Sidwell, Utah State University, Logan, UT; Dr. Brent Korba, Georgetown University, Rockville, MD; and, Dr. John Huggins, the US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, MD 21702.

References

1. Simons, C. Nucleoside Mimetics: Their Chemistry and Biological Properties. Gordon and Breach; Amsterdam: 2001. p. 127-129.
2. (a) Schneller SW. Current Topics in Med Chem 2002;2:1087–1092. (b) Herdewijn P, Balzarini J, De Clercq E, Vanderhaeghe H. J Med Chem 1985;28:1385–1386. [PubMed: 4045916] (c) De Clercq E. Biochem Pharmacol 1987;36:2567–2575. [PubMed: 3300656] (d) Cools M, De Clercq E. Biochem Pharmacol 1989;38:1061–1067. [PubMed: 2539815] (e) Hori M, Ito E, Takita T, Koyama G, Takeuchi T, Umezawa H. J Antibiot 1964;17A:96–99. [PubMed: 14171222] (f) Koyama G, Umezawa H. J Antibiot 1965;18A:175–177. [PubMed: 5898331]
3. (a) Boyer SJ, Leahy JW. J Org Chem 1997;62:3976–3980. (b) Chun BK, Song GY, Chu CK. J Org Chem 2001;66:4852–4858. [PubMed: 11442416] and references cited therein (c) Tuncbilek M, Schneller SW. Bioorg Med Chem 2003;11:3331–3334. [PubMed: 12837543] (d) Zhou J, Yang M, Schneller SW. Tetrahedron Lett 2004;45:8233–8234. (e) Zhou J, Yang M, Akdag A, Schneller SW. Tetrahedron 2006;62:7009–7013.
4. Ugarkar BG, Castellino AJ, DaRe JS, Ramirez-Weinhouse M, Kopcho JJ, Rosengren S, Erion MD. J Med Chem 2003;46:4750–4760. [PubMed: 14561094]
5. (a) Rycroft AD, Singh G, Wightman RH. J Chem Soc, Perkin Trans 1 1995:2667–2668. (b) Buchanan JG, Quijano ML, Wightman RH. J Chem Soc, Perkin Trans 1 1992:1573–1576. (c) Evans GB, Furneaux RH, Gainsford GJ, Hanson JC, Kicska GA, Sauve AA, Schramm VL, Tyler PC. J Med Chem 2003;46:155–160. [PubMed: 12502369] (d) Buchanan JG, Jumaah AO, Kerr G, Talekar RR, Wightman RH. J Chem Soc, Perkin Trans 1 1991:1077–1083. (e) Buchanan JG, Stobie A, Wightman RH. Can J Chem 1980;58:2624–2627.
6. For reviews, see: (a) Posner GH. Org React 1975;22:253–400. (b) Lipshutz BH, Sengupta S. Org React 1992;41:135–631. (c) Bonini C, Righi G. Synthesis 1994:225–238. (d) Comprehensive Organic Synthesis. Trost BM, Pattenden G. 3 Carbon-Carbon –bond Formation Pergamon Press Oxford 1991;

7. (a) Shanmugam P, Miyashita M. *Org Lett* 2003;5:3265–3268. [PubMed: 12943403] (b) Stichler-Bonaparte J, Bernet B, Vasella A. *Helv Chim Acta* 2002;85:2235–2257. (c) Zhou HY, Campbell EJ, Nguyen ST. *Org Lett* 2001;3:2229–2231. [PubMed: 11440586] (d) Sasaki M, Tanino K, Miyashita M. *J Org Chem* 2001;66:5388–5394. [PubMed: 11485460] (e) Tanino K, Honda Y, Miyashita M. *Tetrahedron Lett* 2000;41:9281–9285. (f) Schneider C, Brauner J. *Tetrahedron Lett* 2000;41:3043–3046. (g) Sasaki M, Miyazawa M, Tanino K, Miyashita M. *Tetrahedron Lett* 1999;40:9267–9270. (h) Ishibashi N, Miyazawa M, Miyashita M. *Tetrahedron Lett* 1998;39:3775–3778. (i) Inghardt T, Frejd T. *Tetrahedron* 1991;47:6483–6492. (j) Akita H, Matsukura H, Oishi T. *Tetrahedron Lett* 1986;27:5397–5400. (k) Roush WR, Adam MA, Peseckis SM. *Tetrahedron Lett* 1983;24:1377–1380. (l) Suzuki T, Saimoto H, Tomioka H, Oshima K, Nozaki H. *Tetrahedron Lett* 1982;23:3597–3600.
8. Kuang R, Ganguly AK, Chan TM, Pramanik BN, Blythin DJ, McPhail AT, Saksena AK. *Tetrahedron Lett* 2000;41:9575–9579.
9. Gage JR, Evans DA. *Org Synth* 1990;68:83–87.
10. Crimmins MT, King BW, Zuercher WJ, Choy AL. *J Org Chem* 2000;65:8499–8509. [PubMed: 11112569]
11. Bartlett PA, Tanzella DJ, Barstow JF. *J Org Chem* 1982;47:3941–3945.
12. For leading references for the antiviral and cytotoxicity procedures used (a) Rajappan VP, Schneller SW, Williams SL, Kern ER. *Bioorg Med Chem* 2002;10:883–886.886 [PubMed: 11836094](b) Siddiqi SM, Chen X, Schneller SW, Ikeda S, Snoeck R, Andrei G, Balzarini J, De Clercq E. *J Med Chem* 1994;37:551–554.554 [PubMed: 8120872](c) Chu CK, Jin YH, Baker RO, Huggins J. *Bioorg Med Chem Lett* 2003;13:9–12.12 [PubMed: 12467606](d) <http://www.usu.edu/iar/Brochure/brochure.html>. [August 27, 2007];
13. Wolfe MS, Lee Y, Bartlett WJ, Borcharding DR, Borchardt RT. *J Med Chem* 1992;35:1782–1791. [PubMed: 1588558]
14. (a) Secrist JA III, Shortnacy AT, Montgomery JA. *J Med Chem* 1985;28:1740–1742. [PubMed: 4068000] (b) Dye FJ, Rossomando EF. *Biosci Rept* 1982;2:229–234.

- 1**, R=CH₂OH; R'=H; X=O
3, R=CH₂OH; R'=H; X=CH₂
4, R=H; R'=CH₂OH; X=CH₂

2

Figure 1.

Figure 2.

Figure 3.
X-ray structure for compound 5

Scheme 1a.

^aReaction conditions: *a*, (i) *n*-BuLi/hexanes, THF; (ii) **a**, TBME, 100% for 2 steps; *b*, (i) *n*-Bu₂BOTf, *i*-Pr₂NEt, CH₂Cl₂, -78 °C; (ii) acrolein, -78 °C, CH₂Cl₂, 92% for 2 steps; *c*, 1st gen. Grubbs catalyst, CH₂Cl₂, 59%; *d*, LiBH₄, MeOH, THF, 0 °C, 66%; *e*, *m*-CPBA, CH₂Cl₂; *f*, NaH, BnBr, TBNI, THF, 72% (for steps *e* and *f*).

Scheme 2a.

^aReaction conditions: *a*, Me_3SiCCH , BuLi, -78°C , N_2 followed by Et_2AlCl , 0°C , 62%; *b*, TBAF, THF, 92%; *c*, (i) $n\text{-BuLi}$ /hexanes, TBME followed by DMF; (ii) hydrazine monohydrate, AcOH; (iii) Ac_2O , pyridine, DMAP, 85% for 3 steps; *d*, (i) BBr_3 , CH_2Cl_2 , (ii) Ac_2O , Et_3N , DMAP, CH_2Cl_2 , 76%; *e*, (i) ammonium nitrate, TFA, TFAA; (ii) KCN, EtOH/EtOAc, 88% for 2 steps; *f*, H_2 , Pd/C, MeOH, 92%; *g*, NH_3 , MeOH, 88%; *h*, formamidine acetate, EtOH, 60%.